Need for ARV forecasts

Generic competition has historically been key to reducing prices and increasing access to medicines. Generic drug development processes, from active pharmaceutical ingrediant (API) production to finished drug registration, typically takes at least four years with most companies beginning development work once there is certainty of demand. Without market demand security, generic manufacturers may not be willing to invest in development of promising pipeline antitretrovirals (ARVs) and new chemical entitities, even if voluntary licences are in place.

Forecasting the use of ARVs is key to providing generic manufacturers with guidance and motivation for timely generic development of pipeline ARVs for use in developing countries.

Timely generic development of new drugs may help in the prompt adoption of appropriate drugs in treatment recommendations. Moreover, forecasting guides our industry partners on access strategies, prioritization and builing capacity, therby ensuring industry readiness for timely availability of adequate amounts of recommended drugs thereby helping achieve international treatment targets. They also  provide broad support to the HIV community and support financing agencies in identifying drugs that may optimise spend on treatment. Policymakers, procurement agencies, regulatory agencies and other public health bodies also rely on these analyses to plan their policies and place new drugs on the market.

For the Medicines Patent Pool, forecasts are needed to engage originator companies into licensing their pipeline ARVs, and facilitate decision-making by generic manufacturers for seeking licences and investing in development, production and regulatory approval of needed ARV formulations.

MPP-WHO forecasting collaboration

The MPP and the World Health Organization (WHO) prepare joint forecasts on the use of antiretroviral medicines in developing countries. We work together to pool respective information and insights from  our partners. We review epidemiology data from UNAIDS and model the use and uptake of drugs based on, among other factors:

  • Past trends
  • WHO guidelines
  • Clinical data, including safety and efficacy of drugs
  • Expected date of generic availability
  • Degree of generic competition
  • Availability of FDCs
  • Extent of generic distribution
  • Expected price of drugs over the years
  • Expert opinion.

Experts who have worked with us on these forecasts are associated with World Health Organization, UNAIDS, Avenir Health and University of British Colombia.

MPP-WHO’s forecasting methodology is available for all to review, with methods and results shown both here (see below) and on the WHO website. Notably, the forecasts have been published in the peer-reviewed journal PLOS ONE which is openly accessible. Our forecasts have been presented at multiple international meetings, including IAS and the Joint WHO/UNAIDS annual consultations with manufacturers and partners.

We update our forecasts annually and publish them on our website. Read our published studies and presentations on forecasting methodology and findings below:

Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)
Harvard T.H. Chan School of Public Health/MPP study in peer-reviewed journal PLOS ONE in May 2017 estimating that savings of its licensing agreements for antiretrovirals (ARVs) to treat HIV in low- and middle-income countries could reach US$ 2.3 billion by 2028.
Forecasted demand for current and new ARV medicines in low- and middle-income countries, 2016-2026
WHO/MPP presentation prepared for MPP's third annual industry event in March 2017
Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025
WHO/MPP’s joint work on forecasting the use of antiretrovirals in low and middle-income countries, published in peer-reviewed journal PLOS ONE – October 2016
Forecasted demand for current and new ARV medicines in low and middle income countries, 2015-2025
WHO/MPP forecast excerpts from the Joint WHO/UNAIDS Meeting with Manufacturers and Partners on Global ARV Demand Forecast, March 2016
Forecasted demand for current and new ARV medicines in low and middle income countries, 2014-2025
Presentation prepared for the International AIDS Conference July 2015
Forecasting Pipeline ARVs
Presented at WHO/UNAIDS Annual meeting with Pharmaceutical Companies and Stakeholders in March 2015
Forecasting Pipeline ARVs for Paediatrics
Presented at WHO/UNAIDS Annual meeting with Pharmaceutical Companies and Stakeholders in March 2015
This website uses cookies to ensure you get the best experience on our website. Learn More